Nemonapride

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Nemonapride
Nemonapride.png
Systematic (IUPAC) name
N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide
Clinical data
AHFS/Drugs.com International Drug Names
Legal status Prescription only
Routes Oral
Identifiers
CAS number 75272-39-8
ATC code None
PubChem CID 4452
UNII Q88T5P3444 YesY
KEGG D01468 YesY
Chemical data
Formula C21H26ClN3O2 
Mol. mass 387.90 g/mol
 YesY (what is this?)  (verify)

Nemonapride (Emilace) is an atypical antipsychotic approved in Japan for the treatment of schizophrenia. It was launched by Yamanouchi in 1991. Nemonapride acts as a D2 and D3 receptor antagonist, and is also a potent 5-HT1A receptor agonist. It has affinity for sigma receptors.

See also[edit]

References[edit]